



4th August 2025

The Secretary
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400 001
Scrip Code: 544250

The Secretary
National Stock Exchange of India Limited
C-1, Block G, Exchange Plaza,
Bandra-Kurla Complex,
Bandra East, Mumbai - 400 051
Symbol: SANOFICNR

Sub.: Outcome of Board Meeting held on Monday, 4th August 2025

Dear Sir/Madam,

We refer to our letter dated 29th July 2025 informing you of our Board Meeting that was scheduled today. In this regard, we wish to inform you that the Board of Directors at its meeting held today i.e., Monday, 4th August 2025, *inter-alia* considered and approved the Unaudited Financial Results for the quarter and half year ended 30th June 2025.

Further, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we also enclose herewith a copy of the Unaudited Financial Results for the quarter and half year ended 30th June 2025 approved at this Meeting with a copy of the Limited Review Report duly signed by the Statutory Auditors of the Company. In this regard, please also find enclosed the accompanying press release.

Extract of the aforesaid results will be published in the newspapers in the format prescribed under Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The aforesaid Financial Results will also be available on the Company's website on <https://www.sanofi.com/en/india/consumer-healthcare/investors/financial-results>

The meeting of Board of Directors commenced at 2:30 p.m. and concluded at 6:15 p.m.

Kindly take the above information on record.

Thanking You,

Yours faithfully
For Sanofi Consumer Healthcare India Limited

Nikunj Kumar Savaliya
Company Secretary and Compliance Officer
Membership No.: F7048

**KALYANIWALLA
& MISTRY LLP**

CHARTERED ACCOUNTANTS

REVIEW REPORT

TO THE BOARD OF DIRECTORS

SANOFI CONSUMER HEALTHCARE INDIA LIMITED

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **Sanofi Consumer Healthcare India Limited** ("the Company"), for the quarter and half year ended June 30, 2025 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations"), which has been digitally signed by us for identification purposes.
2. This Statement, which is the responsibility of the Company's Management has been reviewed by the Audit Committee and approved by the Company's Board of Directors at their respective meetings held on August 04, 2025, and has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 ("the Act"), read with the relevant Rules issued thereunder, as applicable and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SREs) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited Financial Results prepared in accordance with the applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For KALYANIWALLA & MISTRY LLP
CHARTERED ACCOUNTANTS**

Firm Registration No. 104607W / W100166

**Sai Venkata Ramana Damarla
Partner**

Membership. No. 107017

UDIN: 25107017BMLFQR8090

Place: Mumbai

Date: August 04, 2025

LLP IN : AAH - 3437

REGISTERED OFFICE : ESPLANADE HOUSE, 29, HAZARIMAL SOMANI MARG, FORT, MUMBAI 400 001

TEL.: (91) (22) 6158 6200, 6158 7200 FAX: (91) (22) 6158 6275

Sanofi Consumer Healthcare India Limited

Registered Office : Unit 1104, 11th Floor, Godrej Two Pirojshanagar, Eastern Express Highway, Vikhroli East, Mumbai, Maharashtra, India, 400079

Corporate Identity Number: U21002MH2023PLC402652

Tel no: (91-22) 45288555

Website: www.sanofi.in Email: igrc.schil@sanofi.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED JUNE 30, 2025

Particulars	₹ in Million					
	Quarter ended 30.06.2025 (Unaudited)	Quarter ended 31.03.2025 (Unaudited)	Quarter ended 30.06.2024 (Unaudited)	Half year ended 30.06.2025 (Unaudited)	Half year ended 30.06.2024 (Unaudited)	Year ended 31.12.2024 (Audited)
1. Revenue from Operations (Refer note 8)	2,209	1,726	1,723	3,935	3,939	7,245
2. Other Income	56	52	8	108	38	130
3. Total Income (1+2)	2,265	1,778	1,731	4,043	3,977	7,375
4. Expenses						
(a) Cost of Materials Consumed	554	189	317	743	985	1,274
(b) Purchases of stock in trade	46	335	-	381	93	421
(c) Changes in Inventories of work-in-progress, stock-in-trade and finished goods	12	(136)	138	(124)	(23)	166
(d) Employee benefits expense	320	296	248	616	477	1,027
(e) Finance costs	5	4	1	9	1	39
(f) Depreciation and amortisation expense	30	20	11	50	20	45
(g) Other expenses (Refer note 8)	575	402	384	977	953	1,651
Total Expenses	1,542	1,110	1,099	2,652	2,506	4,623
5. Profit before exceptional items and tax (3-4)	723	668	632	1,391	1,471	2,752
6. Exceptional items (Refer note 4)	66	-	(243)	66	(243)	(284)
7. Profit before tax (5+6)	789	668	389	1,457	1,228	2,468
8. Tax expense						
Current Tax	184	170	129	354	351	696
Deferred Tax	(2)	(2)	(30)	(4)	(40)	(38)
9. Profit for the period /year (7-8)	607	500	290	1,107	917	1,810
10. Other comprehensive income (OCI)						
Items that will not be reclassified to the statement of profit and loss						
- Remeasurements of post-employment benefit obligations	-	-	-	-	-	(19)
- Income Tax impact relating to these items	-	-	-	-	-	5
11. Total comprehensive income for the period/year (9+10)	607	500	290	1,107	917	1,796
12. Paid-up equity share capital (Face Value of ₹ 10 per share)	230	230	230	230	230	230
13. Other equity	-	-	-	-	-	2,500
14. Basic and diluted earnings per share (not annualised) (in ₹)	26.36	21.69	12.58	48.07	39.82	78.59

The statutory auditors have digitally signed this statement for identification purposes only and this Statement should be read in conjunction with our LODR Regulations review report dated August 04, 2025.

Sanofi Consumer Healthcare India Limited
UNAUDITED STATEMENT OF ASSETS AND LIABILITIES

₹ in Million

Particulars	As at June 30, 2025 (Unaudited)	As at December 31, 2024 (Audited)
ASSETS		
Non-current assets		
Property, plant and equipment	154	97
Capital work in progress	*	7
Right-of-use assets	252	175
Intangible assets	13	19
Financial assets		
Other financial assets	37	36
Income tax assets (net)	37	-
Deferred tax assets (net)	66	62
Total non-current assets	559	396
Current assets		
Inventories	780	409
Financial assets		
(i) Trade receivables	444	137
(ii) Cash and cash equivalents	2,164	3,269
(iii) Bank Balances other than (ii) above	5	-
(iv) Loans	1	6
(v) Other financial assets	11	38
Other current assets	256	58
Total current assets	3,661	3,917
TOTAL ASSETS	4,220	4,313
EQUITY AND LIABILITIES		
Equity		
Equity share capital	230	230
Other equity		
Reserves and Surplus	2,340	2,500
Total equity	2,570	2,730
LIABILITIES		
Non-current liabilities		
Financial liabilities		
Lease liabilities	210	166
Employee benefit obligations	111	111
Total non-current liabilities	321	277
Current liabilities		
Financial liabilities		
(i) Lease liabilities	73	37
(ii) Trade payables		
(a) Total outstanding dues of micro enterprises and small enterprises	24	33
(b) Total outstanding dues of creditors other than micro enterprises and small enterprises	907	670
(iii) Other financial liability	5	-
Employee Benefit Obligations	187	244
Other current liabilities	24	141
Provisions	109	178
Current tax liabilities (net)	-	3
Total current liabilities	1,329	1,306
Total liabilities	1,650	1,583
TOTAL EQUITY AND LIABILITIES	4,220	4,313

*denotes figure less than a million

The statutory auditors have digitally signed this statement for identification purposes only and this Statement should be read in conjunction with our LODR Regulations review report dated August 04, 2025.

Sanofi Consumer Healthcare India Limited
UNAUDITED STATEMENT OF CASH FLOWS FOR THE HALF YEAR ENDED JUNE 30, 2025
₹ in Million

Particulars	Half year ended June 30, 2025 Unaudited	Half year ended June 30, 2024 Unaudited
Cash flows from Operating activities	1,457	1,228
Profit before tax		
Adjustment for :		
Depreciation and amortization expenses	50	20
Unrealised exchange (gain)	(21)	-
Finance costs	9	1
Interest income	(83)	(34)
Share based payment	-	6
Provision for bad and doubtful debts (net)	3	-
Operating profit before working capital changes	1,415	1,221
Adjustments for (increase) / decrease in operating assets		
Non-current financial assets	(1)	(24)
Inventories	(371)	429
Trade receivables	(289)	(9)
Current financial assets	27	1,522
Other current assets	(198)	(116)
Adjustments for increase / (decrease) in operating liabilities		
Employee benefit obligations	(57)	55
Trade payables	183	(316)
Current financial liabilities	5	81
Other current liabilities & provisions	(185)	294
Cash generated from operations	529	3,137
Taxes paid (net of refunds)	(350)	(822)
Net Cash inflow / (outflow) from Operating activities (A)	179	2,315
Cash flows from Investing activities		
Interest received	83	34
Purchase of property, plant and equipment and Intangible assets including Capital work-in-progress	(69)	(2)
Net cash inflow from Investing activities (B)	14	32
Cash flows from financing activities		
Cancellation of Shares issued to SIL	-	(20)
Principal elements of lease payments	(22)	(3)
Interest paid on lease	(9)	(1)
Dividend paid	(1,267)	(1,152)
Net cash used in financing activities (C)	(1,298)	(1,176)
Net increase in cash and cash equivalents (A+B+C)	(1,105)	1,171
Cash and Cash Equivalents at the beginning of the period	3,269	16
Cash and Cash Equivalents at the end of the period	2,164	1,187
Non- cash financing and investing activities		
Acquisition of Right-of-use assets	103	

The statutory auditors have digitally signed this statement for identification purposes only and this Statement should be read in conjunction with our LODR Regulations review report dated August 04, 2025.

Notes:

1. These unaudited financial results have been prepared in accordance with recognition and measurement principles of the Indian Accounting Standards (“Ind AS”), as prescribed under section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and the other accounting principles generally accepted in India.
2. The statutory auditors have issued a limited review report with an unmodified conclusion on the above unaudited financial results for the quarter and half year ended June 30, 2025. The unaudited financial results which are published in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2025 have been reviewed by the Audit Committee in their meeting held on August 4, 2025 and approved by the Board of Directors of the Company at its meeting held on August 4, 2025.
3. Company had during the previous year voluntarily decided to recall Depura Adult, Depura Kids, Allegra Suspension and Combiflam Suspension from distributors, hospitals, and retailers as a precautionary measure. Subsequently, the company has successfully relaunched Depura Adult and Combiflam Suspension during the quarter ended March 2025 and June 2025, respectively. The Company continues to engage in efforts to bring back the rest of the recalled products to the market as soon as possible. To that effect, the results are not comparable with the corresponding quarters and half year.
4. In the quarter ended June 30, 2025, the Company recorded an exceptional gain of ₹66 million from reversing excess demerger-related provisions made in the previous year. Exceptional items for the quarter and half-year ended June 30, 2024 amounts to ₹243 million (year ended December 31, 2024 amounts to ₹ 284 million) which includes product recall related cost, expenses towards listing formalities, demerger expenses. Additionally, year ended December 31, 2024 includes Intangible asset under development written off amounting to ₹ 29 million (acquired under the Scheme of Arrangement)
5. The Company has a single business segment namely ‘Pharmaceutical Business.
6. The Company does not have any subsidiary, associates or joint ventures as on June 30, 2025.
7. On April 30, 2025, Sanofi globally closed the sale to Clayton, Dubilier & Rice Fund XII, L.P. of a 50% controlling stake of Opal JVco S.a.r.l (i.e. Opella group), with Sanofi keeping a significant shareholding of 48.2% stake and Bpifrance owning a 1.8% stake. Consequently, the ultimate Parent of the Company, is now Opal JVco S.a.r.l instead of Sanofi. The said significant change occurred during the quarter ending June 30, 2025.
8. a) Revenue from operations include sale of products as under:

Particulars	₹ in Million					
	Quarter ended			Half year ended		Year ended
	30.06.2025	31.03.2025	30.06.2024	30.06.2025	30.06.2024	31.12.2024
	(Unaudited)			(Unaudited)		(Audited)
Sales of Product	2,023	1,586	1,586	3,610	3,640	6,689

b) During the quarter and half year ended June 2024, certain expenses as stated below were shown net of recoveries. In order to enhance clarity of financial statements, the expenses and revenue from operations have been regrouped as under. This regrouping does not have any financial impact.

₹ in Million

Particulars	Quarter ended 30.06.2024			Half year ended 30.06.2024		
	Previously reported	Increase	Regrouped	Previously reported	Increase	Regrouped
Revenue from Operations	1644	79	1,723	3756	183	3939
Other expenses	305	79	384	770	183	953

The statutory auditors have digitally signed this statement for identification purposes only and this Statement should be read in conjunction with the LODR Regulations review report dated August 04, 2025.

SANOFI CONSUMER HEALTHCARE INDIA LIMITED

Himanshu Bakshi
Managing Director
DIN: 08188412

August 04, 2025

Sanofi Consumer Healthcare India Limited reports 28% revenue growth in Q2

Profit up 21% at ₹607 million

Mumbai, 4th August, 2025: Sanofi Consumer Healthcare India Limited (BSE:544250 | NSE: SANOFICONR) announced strong financial results for the second quarter of 2025. The company reported a 28% year-on-year increase in Q2 revenue to ₹2,209 million, supported by export operations and successful product launches. Thereby, sales growth stood at 27.5% from Q1 2025 and 27.6% YoY from 2024. Profit after tax (PAT) for the quarter reached ₹607 million, a 21% increase over Q1 2025.

Commenting on the results, **Himanshu Bakshi, Managing Director, Sanofi Consumer Healthcare India Limited**, said: *“Our commitment to delivering high-quality, science-backed products continues to anchor our growth strategy—driven by a focused portfolio, research-led innovation, and an agile organization. This quarter reflects the outcomes of that focused approach, with successful relaunch of two previously recalled products and introduction of a new product. We also commenced export operations allowing us to extend our efforts towards international markets. As we look ahead, we remain steadfast in our purpose to make self-care simpler, more accessible and effective for consumers.”*

During the half year, the company launched **Allegra D***, a unique proposition in the Allergy segment, also relaunched **Depura 60k** and **Combiflam Suspension*** which were recalled voluntarily last year. Other legacy brands such as **Avil***, and **Depura** continue to uphold strong consumer trust and drive long-term relevance in their respective categories.

Financial highlights

- Sale of Products
 - Q2 2025: ₹2,209 million
 - H1 2025: ₹3,935 million
- Profit After Tax
 - Q2 2025: ₹606 million
 - H1 2025: ₹1,107 million

Note: *Quarter and half-year financials are not directly comparable due to the demerger and voluntary recall of certain variants of key brands.*

***P.S.:** These medications must be prescribed by a practicing medical professional.

About Combiflam: Launched in 1985 in India, for three decades now Combiflam has cured millions of back, knee, joint, neck, shoulder, fever and body pains. Prescribed variants of Combiflam are tablets, suspensions and cream.

About Allegra: Launched in 1997 in India, this 27 years old brand has seen successful product extensions over the years. From Allegra 120, Allegra 180, Allegra M, Allegra Nasal Spray, Allegra Nasal Duo to now Allegra D. Allegra is used to treat the symptoms of various kinds of allergies in adults and children, some of which are sneezing, itching and hives.

About Sanofi Consumer Healthcare India Limited.

Sanofi Consumer Healthcare India Limited (SCHIL) has emerged as a distinct legal entity following its demerger from Sanofi India Limited. This demerger, executed under the Scheme of Arrangement, was sanctioned by the Mumbai bench of the National Company Law Tribunal and became effective on 1st June 2024. In alignment with Sanofi’s global strategy, SCHIL is now operating independently, with a dedicated focus on the Consumer Healthcare sector.

With an agile business model and strong brands, SCHIL is one of the leading players in India’s consumer healthcare market. Leveraging its global experience in consumer healthcare, Sanofi Consumer Healthcare India Limited (SCHIL) aims to enhance customer wellbeing through its portfolio of products which encompasses Allergy, Digestive Wellness, Pain Care, and Multivitamins and Herbal/Traditional Dietary Supplements. SCHIL’s key brands include Allegra®, DePURA®, Avil®, and Combiflam®. They are dedicated to building a healthier future for their customers by empowering people to take control of their health, through self-care and by addressing their everyday health concerns.

Contacts for Media Relations:

Nida Paloba | +91 9821017561 | nida.paloba@sanofi.com

Agency Contacts:

.....